preceding RFA to Atezo+Bev for HCC patients

Randomized phase II study of preceding radiofrequency ablation to atezolizuma plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041200075

Enrollment

Registered

2020-12-15

Start date

2021-01-18

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma hepatocellular carcinoma

Interventions

Radiofreuquency ablation, Atezolizumab and bevacizumab combination therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent

Exclusion criteria

Exclusion criteria: refractory ascites or pleural effusion; unsuitable for RFA, risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall survival, Immunological response, Objective response rate, Tumor control rate, Subsequent therapy, Adverse events	—

Contacts

Public ContactTakeshi Terashima

Kanazawa University Hospital

tera@m-kanazawa.jp+81-76-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026